ACE Inhibitor

Enalapril: Clinical Studies & Trial Evidence

Enalapril is an ACE inhibitor that lowers blood pressure, reduces cardiac workload, and provides kidney protection in hypertension, heart failure, and diabetic nephropathy.

Mechanism Interactions Evidence Clinical Studies

Grade AGrade A — Landmark RCTs with mortality endpoints, systematic reviews, and ESC/ACC Class I guidelines

ACE inhibitors have landmark mortality trial evidence across heart failure, post-MI, and diabetic nephropathy — with some of the most influential RCTs in cardiovascular medicine.

Key Clinical Trials

CONSENSUS — Cooperative North Scandinavian Enalapril Survival Study

1987

Population: 253 patients with NYHA Class IV (severe) heart failure

Primary endpoint: All-cause mortality

Enalapril reduced 6-month mortality by 40% vs placebo (p=0.002). Landmark trial establishing ACE inhibitor survival benefit in severe HF.

NEJM 1987; 316(23): 1429–1435

SOLVD — Studies of Left Ventricular Dysfunction

1991

Population: 2,569 patients with asymptomatic LV dysfunction (EF ≤35%)

Primary endpoint: All-cause mortality or HF hospitalisation

Enalapril reduced mortality by 16% and HF hospitalisation by 26% vs placebo. Established benefit in asymptomatic LV dysfunction.

NEJM 1992; 327(10): 685–691

HOPE — Heart Outcomes Prevention Evaluation

2000

Population: 9,297 high-risk patients ≥55y without HF or low EF

Primary endpoint: CV death, MI, or stroke (composite)

Ramipril reduced primary endpoint by 22% vs placebo (p<0.001). Benefit extended beyond BP reduction — direct cardioprotective effect postulated.

NEJM 2000; 342(3): 145–153

Lewis et al. — Captopril in Diabetic Nephropathy

1993

Population: 409 patients with type 1 diabetes + proteinuria

Primary endpoint: Doubling of serum creatinine or ESRD/death

Captopril reduced risk of doubling creatinine by 48% vs placebo, independent of BP. Established ACE inhibitor as renoprotective in diabetic nephropathy.

NEJM 1993; 329(20): 1456–1462

Numbers Needed to Treat (NNT / NNH)

HF mortality (CONSENSUS): NNT ≈ 9 over 6 months. Post-MI survival (meta): NNT ≈ 30 over 5 years. Diabetic nephropathy (ESRD prevention): NNT ≈ 8 over 3 years. High-risk CV prevention (HOPE): NNT ≈ 26 to prevent 1 MI/stroke/CV death over 4.5 years.

Systematic Reviews & Meta-Analyses

•Flather et al. (Lancet 2000) — ACE inhibitors in acute MI: mortality RR 0.82 (95% CI 0.74–0.91)
•Garg & Yusuf (JAMA 1995) — ACE inhibitors in HF: 23% mortality reduction in meta-analysis of 32 trials
•Strippoli et al. (Cochrane 2006) — ACE inhibitors reduce ESRD and mortality in diabetic nephropathy
•Blood Pressure Lowering Treatment Trialists' Collaboration (Lancet 2000) — class effects vs comparators

Guideline Endorsements

✓ESC HF Guidelines 2021 — Class I, Level A: ACE inhibitor (or ARNi) for all HFrEF to reduce mortality
✓ACC/AHA HF Guidelines 2022 — Stage B/C HF: ACE inhibitor/ARB/ARNi, Class I
✓NICE NG106 (2018) — ACE inhibitor first-line for CKD with diabetes + albuminuria
✓ESC/EACTS 2018 Myocardial Revascularisation — ACE inhibitor post-MI with LV dysfunction
✓ADA Standards of Care 2023 — ACE inhibitor/ARB for diabetic nephropathy with albuminuria

Comparative Effectiveness

↔ACE inhibitors vs ARBs: equivalent efficacy for HF and CKD; ACE inhibitors cause cough (15–20%), ARBs do not
↔ACE inhibitors vs beta-blockers: complementary in HF — ESC guidelines recommend both
↔ACE inhibitors vs ARNi (sacubitril/valsartan): PARADIGM-HF 2014 — ARNi superior in HFrEF; ARNi now preferred first-line where available
↔Ramipril vs atenolol (HOPE vs ASCOT sub-analysis): ramipril superior CV outcomes beyond BP effect

Key Safety Signals

Dry cough in 15–20% — class effect from bradykinin accumulation; switch to ARB if intolerable. Angioedema rare (<1%) but potentially life-threatening — especially in Black patients (higher incidence). First-dose hypotension in volume-depleted patients. Hyperkalemia risk (monitor K+ in CKD or with potassium-sparing diuretics). Fetotoxic — contraindicated in pregnancy (FDA Category D/X in 2nd/3rd trimester). Acute kidney injury with bilateral renal artery stenosis.

Evidence Limitations

!HFrEF evidence predates widespread use of ARNi/SGLT2 inhibitors — comparative effectiveness in modern HF quadruple therapy less established
!Most landmark trials (CONSENSUS, SOLVD) enrolled predominantly male, White European populations
!CKD nephroprotection evidence primarily in type 1 DM (Lewis 1993); type 2 DM evidence for ARBs stronger
!HOPE benefits may partly reflect low baseline ACE inhibitor use rather than drug superiority

Conditions Treated with Enalapril

Heart FailureHow used →Chronic Kidney Disease (CKD)How used →HypertensionHow used →

Questions about Enalapril?

Our AI Symptom Checker analyses your symptoms, suggests diagnoses, and identifies relevant medications — including clinical evidence summaries.

Use AI Symptom Checker →